MedTrace Logo

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

NCT04882371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2021-05-11

No results posted yet for this study

Summary

The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast cancer to neoadjuvant chemotherapy (NAC).

Conditions

Interventions

DRUG

Chemotherapy

Neoadjuvant Chemotherapy for Breast Cancer

DIAGNOSTIC_TEST

Magnetic Resonance Imaging (MRI)

Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy

DIAGNOSTIC_TEST

Positron emission tomography - Copmputer Tomography (PET-CT)

Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy

Sponsors & Collaborators

  • Cem Ilgin Erol

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-05-01
Completion
2020-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04882371 on ClinicalTrials.gov